(Bloomberg) --

Brii Biosciences Ltd. said additional results of a late-stage study of a Covid-19 therapy confirmed a significantly reduced risk of death and hospitalization. 

The topline data readout from the National Institutes of Health-sponsored trial showed combined hospitalization and death risk cut by 80% for “non-hospitalized Covid-19 patients at high risk of clinical progression,” the Chinese company said in a Hong Kong stock exchange filing Sunday. That’s was in line with a 78% reduction disclosed in August, based on an interim analysis. 

In-vitro testing data suggest the therapy is able to treat those with Covid-19 variants including delta, Brii said, while efforts are ongoing to determine effects against the emerging omicron variant. 

The company’s stock surged last month after a state-run publication said China may approve Brii’s antibody-based Covid drug by December. The same publication separately reported a phase 3 trial saw no deaths. 

©2021 Bloomberg L.P.